Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.5 (
cathepsin D
)
4,130
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Studies have compared "total", HMW
kininogen
and leukokininogen levels in human, rabbit and rat plasma using trypsin, glass powder and
cathepsin D
as kininogenases or activators of kininogenases. Rat plasma was found to have about 10 fold more leukokininogen than the other plasmas assayed. When trypsin was used to estimate total
kininogen
, rat plasma liberated maximal amounts of kinin only in the presence of high concentrations of trypsin (1 mg/ml incubation mixture). In addition, it was found that trypsin in these concentrations liberated from rat plasma both
bradykinin
and a previously unidentified kinin which we have termed "T-kinin". The results overall indicate that in the case of rat and rabbit plasma, currently used methods for estimations of total
kininogen
may not be accurate. T-kinin may represent a leukokininogen or a hitherto undescribed
kininogen
.
...
PMID:Kininogen substrates for trypsin and cathepsin D in human, rabbit and rat plasmas. 655 Jul 7
The kinin-forming enzyme of rat brain was studied by bioassaying kinin using a rat uterus. The enzyme released a kinin from the partially purified
kininogen
of rat plasma. The activity is exclusively distributed in the mitochondrial fraction and was detected in the pH range of 2.5-4.0 (optimally at pH 3.0). The enzyme was potently inhibited by pepstatin, but not by aprotinin. Released kinin was extracted by n-butanol and it was purified using Amberlite CG-50 absorption and CM-cellulose column chromatography. The elution profile of kinin from the CM-cellulose column did not coincide with that of
bradykinin
, Lys-
bradykinin
or Met-Lys-
bradykinin
. Isolated kinin was inactivated by treatment with chymotrypsin, but not with trypsin. In addition to the contractile activity on rat uterus, the kinin caused contraction of guinea pig ileum, with the response being potentiated by the presence of
bradykinin
-potentiator B. It also relaxed a rat duodenum, decreased rat blood pressure, and increased the vascular permeability in guinea pigs. Relative potencies of kinin on these pharmacological activities did not coincide with those of
bradykinin
. From these results, it is concluded that a kinin-forming enzyme is present in the rat brain. It is a
cathepsin D
-like enzyme, and furthermore, the enzyme releases a kinin-like peptide from the plasma
kininogen
fraction.
...
PMID:Kinin-forming enzyme in rat brain mitochondria fraction and biological activity of a kinin released from rat plasma kininogen by this enzyme. 674 70
The effects of inhibitors on the kinin-forming enzyme (KFE) activity in the rat stomach were investigated at pH 4.8. The KFE activity was unaffected by trasylol (200 KIU/ml), soybean trypsin inhibitor (100 microgram/ml) and p-tosyl-L-lysine-chloromethyl ketone (10-3 M), but was inhibited by pepstatin A (10(-6) M) and chymostatin (1.5 x 10(-4) M). Each product from the rat plasma
kininogen
by the rat stomach KFE and the bovine spleen
cathepsin D
was eluated at the same retention time on the equilibrium chromatography on the SP-Sephadex C-25 column. The KFE activity in the rat stomach was considerably high compared with that in various regions of the intestine. These results suggest that the KFE is characteristically similar to
cathepsin D
, and the enzyme is probably relevant to the function of the stomach.
...
PMID:Property of kinin-forming enzyme in rat stomach. 691
The kininogenase activity of highly purified preparations of cathepsins D from human liver and spleen, leukemic infiltrate obtained from patients with myeloic leukemia, and from chicken liver was studied. It was found that pepstatin, a specific inhibitor of carboxylic proteinases, inhibits this activity of cathepsins D. Interaction of chicken liver
cathepsin D
with human plasma substrate, which is possibly a low molecular weight
kininogen
(Ks = 1.3.10(-7) M) results in a production of the bradikinin analog methionyl-lysyl-bradikinin. The role of cathepsins D as potent inflammatory agents responsible for the generation of biologically active peptides--mediators of inflammation from the protein substrates including kininogens under desintegration of lysosomes is discussed.
...
PMID:[Kininogenase activity of cathepsins D]. 694 16
Cathepsin D, matrix metalloproteinase (MMP)-2, MMP-3 (stromelysin), and MMP-9 were isolated from rat granulomatous tissues. HT1080 human fibrosarcoma cells and rheumatoid synovial cell CM. At acidic conditions,
cathepsin D
cleaved T-
kininogen
into small peptides and released Met-T-kinin-Leu (kinin precursor), but failed to release kinin. MMP-3 cleaved T-
kininogen
into a 57 kDa fragment as measured by SDS-PAGE and Western blot analysis using anti-T-
kininogen
antiserum. On the other hand, no degradation of T-
kininogen
occurred during incubation with MMP-2 or MMP-9100/1) at pH 7.5 for 7 h.
...
PMID:Degradation of T-kininogen by cathepsin D and matrix metalloproteinases. 879 70
An acidic proteinase was purified from human kidney cortex. The enzyme showed a molecular mass of 31 kDa by SDS-PAGE, 36 kDa by gel filtration, and isoelectric points of 5.2 and 6.1. The optimum pH for hydrolysis of bovine hemoglobin was about 3.5. Reverse-phase HPLC analysis of the incubation mixture of the enzyme with human plasma showed the presence of an active peptide on rat uterus muscle with the same retention time as the methionyl-lysyl-
bradykinin
(MLBK) standard. The specific activities were 2.91 micrograms MLBK equivalent mg-1.min-1 at pH 3.5 and 2.15 micrograms MLBK equivalent mg-1.min-1 at pH 6.0. All the enzymatic activities of this human kidney proteinase were inhibited by pepstatin A. Intramolecularly quenched fluorogenic substrates with amino acid sequences of human
kininogen
were used to determine the cleavage points. On the N-terminal sequences (Abz-Leu-Met-Lys-Arg-Pro-Eddnp and Abz-Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Eddnp) the cleavage occurred at the Leu-Met linkage, and on the C-terminal sequences (Abz-Phe-Arg-Ser-Ser-Arg-Eddnp and Abz-Phe-Arg-Ser-Ser-Arg-Gln-Eddnp) the cleavage occurred at the Arg-Ser linkage. Abz-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-Ser-Ser-Arg-Gln-Eddnp++ + was hydrolyzed by the renal acidic proteinase and yielded the peptide Abz-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (Abz-
bradykinin
). Kinectic parameters were determined using Abz-Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Eddnp (K(m) = 0.69 +/- 0.08 microM; Kcat = 0.052 +/- 0.0095 s-1; Kcat/K(m) = 0.075 +/- 0.005 microM-1.s-1) and Abz-Phe-Arg-Ser-Ser-Arg-Gln-Eddnp (K(m) = 1.56 +/- 0.16 microM; Kcat = 0.0048 +/- 0.0001 s-1; Kcat/K(m) = 0.003 +/- 0.0003 microM-1.s-1). Human liver
cathepsin D
had no activity on C-terminal sequences and human pepsin hydrolyzed them at the Ser-Ser bond. The results suggest that the renal acid proteinase is distinct from human pepsin and human liver
cathepsin D
and releases MLBK from human
kininogen
.
...
PMID:Characterization of kininogenase activity of an acidic proteinase isolated from human kidney. 927 60
<< Previous
1
2